American Journal of Kidney Diseases
Volume 51, Issue 5 , Pages 724-731 , May 2008

Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy: An Uncontrolled Trial

Received 20 August 2007 ,Accepted 12 December 2007.

References 

  1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;245:709–727
  2. Li PKT, Ho KKL, Szeto CC, Yu LM, Lai FM. Prognostic indicators of IgA nephropathy in the Chinese—Clinical and pathological perspectives. Nephrol Dial Transplant. 2002;17:64–69
  3. Haas M. Histologic subclassification of IgA nephropathy: A clinico-pathologic study of 244 cases. Am J Kidney Dis. 1997;29:829–842
  4. Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant. 1994;9:265–269
  5. Russo D, Pisani A, Balletta MM, et al. Additive anti-proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33:851–856
  6. Perico N, Remuzzi A, Sangalli F, et al. The antiproteinuria effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol. 1998;9:2308–2317
  7. Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–760
  8. Coppo R, Peruzzi L, Amore A, et al. IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880–1888
  9. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis. 2000;35:1155–1165
  10. Dillon JJ. Treating IgA nephropathy. J Am Soc Nephrol. 2001;12:846–847
  11. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: A randomized controlled trial. Lancet. 1999;353:883–887
  12. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 1998;53:1696–1705
  13. To KF, Choi PC, Szeto CC, et al. Outcome of IgA nephropathy in adults graded by chronic histological lesions. Am J Kidney Dis. 2000;35:392–400
  14. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937–2944
  15. Jones G, Strugnell SA, Deluca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998;78:1193–1232
  16. Brown AJ. Vitamin D analogues. Am J Kidney Dis. 1998;32(suppl 2):S25–S39
  17. Abe J, Takita Y, Nakano T, Miyaura C, Suda T, Nishii Y. A synthetic analogue of vitamin D3, 22-oxa-1α,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology. 1989;124:2645–2647
  18. Abe H, Iehara N, Utsunomiya K, Kita T, Doi T. A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-β type II receptor-mediated manner. J Biol Chem. 1999;274:20874–20878
  19. Makibayashi K, Tatematsu M, Hirata M, et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol. 2001;158:1733–1741
  20. Li Y, Spataro BC, Yang J, Dai C, Liu Y. 1,25-Dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int. 2005;68:1500–1510
  21. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol. 2004;286:F526–F533
  22. Hirata M, Makibayashi K, Katsumata K, et al. 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant. 2002;17:2132–2137
  23. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823–2828
  24. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229–238
  25. Mizobuchi M, Morrissey J, Finch JL, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol. 2007;18:1796–1806

 Originally published online as doi:10.1053/j.ajkd.2007.12.038 on March 28, 2008.

 Trial registration: www.clinicaltrials.gov; study number: NCT00319761.

PII: S0272-6386(08)00155-8

doi: 10.1053/j.ajkd.2007.12.038

American Journal of Kidney Diseases
Volume 51, Issue 5 , Pages 724-731 , May 2008

Article Tools

* Image Usage & Resolution